Pathogenic sequence variants in the Sorting Nexin 10 (SNX10) gene have been associated with autosomal recessive osteopetrosis (ARO) in human. In this study, an induced pluripotent stem cell (iPSC) line (ARO-iPSC1-11) was generated from an ARO patient carrying the homozygous c.212 + 1G N T mutation in SNX10, using a retroviral-based reprogramming protocol. Characterization confirmed that the generated iPSCs expressed pluripotency markers, displayed normal karyotype, showed pluripotent differentiation capacity and retained the targeted mutation. Disease modeling with this ARO patient-specific iPSC line will shed further light on the critical role of the SNX10 mutation in ARO development.
Cell line repository/bank ARO-iPSC1-11 has been registered in hPSCreg Ethical approval
The Regional Ethical Review Board at Umeå University, Umeå, Sweden, approved the study (2011-327-31M) . Patients gave their written informed consent for skin biopsy donation
In this study, a patient specific iPSC line was created to investigate the molecular and cellular pathologies of ARO associated with a mutation c.212 + 1G N T in the SNX10 gene. In particular, the iPSC-derived model will elucidate the mechanisms underlying osteoclast dysfunction associated with aberrant ruffled border formation and bone resorption.
Resource details
Autosomal recessive osteopetrosis (ARO) is a rare heterogeneous disorder, diagnosed by increased bone density in early infancy associated with dysfunctional osteoclasts in bone resorption. Genetic association analysis revealed the relationship between mutations in SNX10 gene and ARO pathogenesis. In 2013, Pangrazio and his colleagues first discovered a homozygous c.212 + 1G N T (g.72742G N T) mutation in SXN10 carried by ARO patients (Pangrazio et al., 2013) . A later study showed that this mutation can result in dysfunctional osteoclasts by disturbing the formation of ruffled borders in the cells (Stattin et al., 2017) . In order to further understand the molecular mechanisms and Stem Cell Research 24 (2017) 
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Stem Cell Research j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / s c r consequences of the SNX10 mutation in ARO development, we generated iPSCs from a 41-year-old female ARO patient, who carries the homozygous c.212 + 1G N T (g.72742G N T) mutation in SXN10. In total, 18 iPSC-like colonies were generated from the patient's dermal fibroblasts (DFs) using retroviral plasmids containing hOCT4, hSOX2, hC-MYC and hKLF4. The iPSC colony (ARO-iPSC1-11) reported in this publication was randomly selected from these colonies and was successfully established in culture. Mycoplasma testing proved that ARO DFs and ARO-iPSC1-11 cell line derived from these were free from contamination ( Fig. 1F and Table 1 ). Short tandem repeat analysis (STR) showed an identical DNA profile between the donor's fibroblasts and the derived iPSCs (Table S1 ). G-banding analysis proved that ARO-iPSC1-11 carried a normal karyotype ( Fig. 1E and Table 1 ). Furthermore, genomic DNA sequencing verified that the disease related mutation (g.72742G N T) was retained in the generated iPSCs ( Fig. 1D and Table 1 ). To evaluate the pluripotent state of ARO-iPSC1-11, gene expression analysis confirmed the positive expression of endogenous (Endo) pluripotency genes (OCT4, SOX2 and NANOG), but silencing of reprogramming factors expressed by the retroviral transgenes (Tg) (Tg-OCT4, Tg-SOX2, Tg-KLF4 and Tg-C-MYC) (Fig. 1B and C and Table 1 ). Immunofluorescent staining demonstrated that ARO-iPSC1-11 also expressed the pluripotency markers (OCT4, SOX2, NANOG and TRA1-60) at the protein level (Fig .   Fig. 1 . Characterization of the generated iPSCs (ARO iPSC1-11). The expressions of α-smooth muscle actin, β3-tubulin and α-feto protein were examined by immunofluorescent staining Table 1 ). The homologous iPSC population was further confirmed by FACS analysis using antibody against embryonic antigen-4 (SSEA4). The isotype control is represented by the dotted line histogram. The results demonstrated that 100% of the cells were SSEA4 positive (the black histogram, Fig. 1G and Table 1 ). Finally, we assessed the functional pluripotency through embryoid body (EB) formation in vitro. The EBs were maintained in suspension culture up to 35 days before immunohistological analysis ( Fig. 1H and Table 1 ). The results confirmed that ARO-iPSC1-11 cells were able to differentiated into cells from the three germ layers, indicated by the expression of endodermal (α-fetal protein (AFP)), mesodermal (α-smooth muscle actin (αSMA)) and ectodermal (Nestin) markers in the EBs (Fig. 1I and Table 1 ). Therefore, this ARO patient-specific iPSC line containing the SNX10 mutation will provide opportunities to study the pathobiology of SNX10-dependent ARO, and potentially also provide a testing platform for screening therapeutic agents.
Materials and methods iPSC generation
ARO DFs were maintained in medium containing Minimum Essential Medium-alpha, 10% fetal bovine serum (FBS) and 1% PenicillinStreptomycin (10,000 U/mL) (Invitrogen). iPSCs were generated using retroviral vectors encoding hOCT4, hSOX2, hKLF4 and hC-MYC (Addgene). Retroviral reprogramming factors were generated by 293T cells as described previously (Zhang et al., 2011) . Reprogramming was initiated by viral infection of the DFs followed by reseeding the infected fibroblasts in irradiated mouse embryonic fibroblast (VH Bio)-coated tissue culture plates with iPSC medium containing Knockout Dulbecco's Modified Eagle Medium (KO-DMEM), 20% knockout serum replacement, 1 mM L-glutamine, 0.1 mM non-essential amino acids (NEAA), 0.1 mM 2-mercaptoethanol (Invitrogen), and 10 ng/mL fibroblast growth factor-basic (Peprotech). 0.5 mM valproic acid (Millipore) was added before the detection of cells undergoing mesenchymal-epithelial transition. Finally, formed iPSC like colonies were mechanically picked and maintained in geltrex-coated plates (1:100, Invitrogen) with mTeSR™1 medium (Stemcell Technologies Inc).
Karyotype analysis
Chromosomal spreads were prepared as described previously (Xu et al., 2016) . Standard G-banding analysis was performed by The Doctors Laboratory, London, where 20 G-banded metaphases were examined per sample. Gain of the same chromosome or a chromosome structural change seen in two or more cells, or loss of the same chromosome in 3 or more cells was taken to indicate an abnormal karyotype in the iPSC cell line (Table 1) .
Mutation verification
Genomic DNA was extracted using DNeasy Blood & Tissue Kits (Qiagen). The mutation region was amplified by polymerase chain reaction (PCR) using SNX10 primers (Table 2 ). For sequencing, PCR products were purified by Gel Extraction Kit (Qiagen) and analyzed by Eurofins MWG Operon (Germany).
Gene expression analysis
Total RNA was obtained by RNeasy Mini Kit and DNAse I (Qiagen). Complementary DNA was synthesized from RNA (1 μg) by SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen). PCR was performed by OneTaq 2× Master Mix (BioLabs) using primers listed in Table 2 . Positive controls (PC) and no template controls (NTC) were included in all PCR reactions. For detection of Endo pluripotency genes, PCs were prepared from another qualified iPSC line. For determination of retroviral Tgs, PCs were obtained from retroviral-infected 293T cells. GAPDH was used as a loading control. 
Protein analysis
In order to assess the pluripotency markers qualitatively and quantitatively in iPSCs culture, immunofluorescent staining (IFS) and FACS analysis were performed as described previously (Xu et al., 2016) . Antibodies used for IFS and FACS are listed in Table 2 .
EB formation and examination
Dissociated iPSC colonies were transferred into a suspension culture with EB formation medium, containing KO-DMEM supplemented with 10% FBS, 1 mM L-glutamine, 0.1 mM NEAA. The formed EBs were fixed in 4% paraformaldehyde at day 35, followed by paraffin embedding and sectioning. IFS was performed with antibodies against AFP, ɑSMA and Nestin (Table 2 ). Cell nuclei were labeled by DAPI (Invitrogen).
Mycoplasma detection
MycoTrace PCR Kit (PAA) was applied according to the manufacturer's protocol. PC and NTC were included.
Cell line authentication
Genomic DNA was extracted from both DFs and iPSCs using DNeasy Blood & Tissue Kits (Qiagen). STR analysis was performed at Eurofins Genomics.
